Literature DB >> 30179855

Understanding the role of dopamine in conditioned and unconditioned fear.

Marcus L Brandão1,2, Norberto C Coimbra1,2,3.   

Abstract

Pharmacological and molecular imaging studies in anxiety disorders have primarily focused on the serotonin system. In the meantime, dopamine has been known as the neurotransmitter of reward for 60 years, particularly for its action in the nervous terminals of the mesocorticolimbic system. Interest in the mediation by dopamine of the well-known brain aversion system has grown recently, particularly given recent evidence obtained on the role of D2 dopamine receptors in unconditioned fear. However, it has been established that excitation of the mesocorticolimbic pathway, originating from dopaminergic (DA) neurons from the ventral tegmental area (VTA), is relevant for the development of anxiety. Among the forebrain regions innervated by this pathway, the amygdala is an essential component of the neural circuitry of conditioned fear. Current findings indicate that the dopamine D2 receptor-signaling pathway connecting the VTA to the basolateral amygdala modulates fear and anxiety, whereas neural circuits in the midbrain tectum underlie the expression of innate fear. The A13 nucleus of the zona incerta is proposed as the origin of these DA neurons projecting to caudal structures of the brain aversion system. In this article we review data obtained in studies showing that DA receptor-mediated mechanisms on ascending or descending DA pathways play opposing roles in fear/anxiety processes. Dopamine appears to mediate conditioned fear by acting at rostral levels of the brain and regulate unconditioned fear at the midbrain level.

Entities:  

Keywords:  amygdala; dopamine; midbrain tectum; threat

Mesh:

Substances:

Year:  2019        PMID: 30179855     DOI: 10.1515/revneuro-2018-0023

Source DB:  PubMed          Journal:  Rev Neurosci        ISSN: 0334-1763            Impact factor:   4.353


  6 in total

1.  Synthesis and dopamine receptor binding of dihydrexidine and SKF 38393 catecholamine-based analogues.

Authors:  Suzane Rosa da Silva; Predrag Kalaba; Anna Fabišiková; Martin Zehl; Vladimir Dragačević; Luana Ribeiro Dos Anjos; Philip John Neill; Marcus Wieder; Alexander Prado-Roller; Natalie Gajic; Vinicius Palaretti; Gil Valdo Jose da Silva; Christian Pifl; Gert Lubec; Eduardo R Perez Gonzalez
Journal:  Amino Acids       Date:  2021-11-29       Impact factor: 3.520

2.  Brain Mitochondrial Dysfunction: A Possible Mechanism Links Early Life Anxiety to Alzheimer's Disease in Later Life.

Authors:  Qixue Wang; Mengna Lu; Xinyu Zhu; Xinyi Gu; Ting Zhang; Chenyi Xia; Li Yang; Ying Xu; Mingmei Zhou
Journal:  Aging Dis       Date:  2022-07-11       Impact factor: 9.968

3.  Age- and sex-specific fear conditioning deficits in mice lacking Pcdh10, an Autism Associated Gene.

Authors:  Sarah L Ferri; Holly C Dow; Hannah Schoch; Ji Youn Lee; Edward S Brodkin; Ted Abel
Journal:  Neurobiol Learn Mem       Date:  2020-12-16       Impact factor: 2.877

Review 4.  Current Understanding of the Neurobiology of Agitation.

Authors:  Christopher W T Miller; Vedrana Hodzic; Eric Weintraub
Journal:  West J Emerg Med       Date:  2020-07-02

Review 5.  Role of the dorsal periaqueductal gray in posttraumatic stress disorder: mediation by dopamine and neurokinin.

Authors:  M L Brandão; T A Lovick
Journal:  Transl Psychiatry       Date:  2019-09-17       Impact factor: 6.222

6.  Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear.

Authors:  Matthias F J Sperl; Christian Panitz; Nadine Skoluda; Urs M Nater; Diego A Pizzagalli; Christiane Hermann; Erik M Mueller
Journal:  Int J Neuropsychopharmacol       Date:  2022-09-28       Impact factor: 5.678

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.